Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged between 12 and 60 years;~* Written and signed informed consent;~* Was examined by a study physician before treatment;~* Provided two stool samples at baseline;~* Hookworm EPG \> 48 and at least two Kato-Katz thick smears slides with more than one hookworm eggs.~Exclusion Criteria:~* Pregnant or lactating and/or planning to become pregnant within three months after drug treatment;~* Type 1 and/or 2 diabetes;~* Psychiatric disorders;~* History of ophthalmological conditions;~* Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment;~* Suffers from severe anaemia (Hb \< 80 g/l);~* Received anthelminthic treatment within past four weeks;~* Attending other clinical trials during the study;~* Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin;~* Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir.~* Participated in stage I trials of this protocol

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Emodepside 30 mg (Type: EXPERIMENTAL): None
- Albendazole 400 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).